In the efficacy-evaluable population for ROZLYTREK, 41% had NTRK1 gene fusions, 2% had NTRK2 gene fusions, and 57% had NTRK3 gene fusions 1

There is no FDA-approved companion diagnostic for ROZLYTREK. 1

 

  • NTRK gene fusions have been found in >25 tumor types, including 2,5,6
ETV6=ETS variant 6; FDA=US Food and Drug Administration; FISH=fluorescence in situ hybridization; IHC=immunohistochemistry; MASC=mammary analogue secretory carcinoma; NGS=next-generation sequencing; NTRK=neurotrophic receptor tyrosine kinase; RT-PCR=reverse transcription polymerase chain reaction.

Available NGS platforms for TRK testing include:

  • The list provided below may include some tests that are not FDA approved. Contact the individual lab for more information regarding a specific test. This list is non-exhaustive and is not intended to be a recommendation or endorsement of a specific laboratory or test

Cancer Genetics Incorporated

Caris Life Sciences

Foundation Medicine

Integrated Oncology

Intermountain Precision Genomics

Knight Diagnostic Laboratories, Oregon Health & Science University

Mayo Clinic Laboratories

NeoGenomics Laboratories

Paradigm Diagnostics, Inc.

PathGroup

List is current as of August 2019.

ROZLYTREK Efficacy in NTRK Fusion-Positive Solid Tumors

Efficacy Across Tumor Types in Patients With NTRK Fusion-Positive Solid Tumors

View systemic efficacy data in patients with NTRK fusion-positive solid tumors, including response rates by tumor type

Intracranial Efficacy in NTRK Fusion-Positive Solid Tumors

CNS Efficacy in Patients With NTRK Fusion-Positive Solid Tumors

View intracranial efficacy results in patients with NTRK fusion-positive solid tumors

ROZLYTREK Financial Resources

Financial and Other Resources

Learn more about financial and other resources for ROZLYTREK